To our knowledge, this is the first analysis reporting the application of supervised machine learning techniques for predictive modeling to data from a hemophilia clinical trial (namely the pathfinder 2 trial in the setting of prophylaxis with the EHL recombinant FVIII molecule N8-GP). This evidence concerns the gene F8 and hemophilia.